Table 1.

Demographic characteristics and clinical outcome of the 77 AML patients according to normal (n = 37) or elevated (n = 40) serum YKL-40 before start of chemotherapy

CharacteristicsNormal serum YKL-40High serum YKL-40P
Age (y)*58 (18-75)63 (19-77)0.61
Sex (male/female)20/1722/181.0
Cytogenetic type, favorable/intermediate/adverse prognosis3/23/60/28/50.20
AML FAB§ type M2, M3, M4 vs. other15/2225/150.07
AML FAB§ type M4, M5 vs. other13/2413/270.81
Fever at day 1 (n, %)6 (16%)16 (40%)0.025
Proportion (%) of study period with >37.0°C*57 (7-100)70 (0-100)0.067
Proportion (%) of study period with >38.0°C*27 (0-89)38 (0-100)0.28
Proportion (%) of study period with leucopenia (<1.0 × 109/L)*50 (0-89)50 (0-100)0.36
Proportion (%) of study period on antibacterial antibiotics*50 (14-82)60 (0-100)0.14
Antifungal treatment (n, %)21 (57)18 (45)0.37
  • * Values are median (range) and Mann-Whitney test.

  • Values and Fisher's exact test.

  • Intermediate versus adverse prognosis group.

  • § FAB classification.

  • Not significant.